Updated: Acadia wins first FDA approval for Rett syndrome drug

Paul Schloesser

Associate Editor

Drew Armstrong

Executive Editor

The FDA on Friday approved Acadia Pharmaceuticals’ treatment for Rett syndrome, a rare neurodevelopmental disorder, which will be sold under the brand name Daybue …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Acadia wins first FDA approval for Rett syndrome drug

Paul Schloesser

Associate Editor

Drew Armstrong

Executive Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Sofinnova outlines $550M fund after IPOs and M&A deals

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Exclusive: Florida cancer biotech raises $100M Series A

Up­dat­ed: Aca­dia wins first FDA ap­proval for Rett syn­drome drug

Associate Editor

Executive Editor

Sign up to read this article for free.

more like this

Updated: Acadia wins first FDA approval for Rett syndrome drug